Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
In contrast to previous studies, targeting the mGluR pathway in fragile X syndrome patients did not improve behavior independent of FMR1 methylation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unemployment is high in this population, and even among those employed, individuals are often working below their skills and abilities 220,221 .”
From Autism spectrum disorder (2020) · cites this paper as [221]
In the citing paper
“However, several drug development programs based on the inhibition of mGluR signaling for the treatment of FXS (Novartis and Seaside Therapeutics) were recently closed because efficacy studies in adolescents and adults showed no measurable benefits 114,115 .”
From Developmental timing and critical windows for the treatment of psychiatric disorders (2016) · cites this paper as [114]
In the citing paper
“Exploratory biomarkers and endophenotypes tested in a substudy (n = 56) of the mavoglurant trials suggests an improvement relative to placebo in gaze towards the eye region on an eye-tracking task and in performance on a computerized executive function battery69.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [69]
In the citing paper
“Mild side effects (headaches, dizziness, insomnia and vomiting) were observed in about 20% of FXS patients with mavoglurant at higher dose levels69.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [69]
In the citing paper
“Conversely, the larger studies of mavoglurant, basimglurant and arbaclofen included over 100 participants and were able to provide conclusions across secondary outcome measures69.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [69]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481
Systematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
Validation of the NPI-Q, a Brief Clinical Form of the Neuropsychiatric Inventory
Kaufer, D., Cummings, J. L., Ketchel, P., Smith, V. M., MacMillan, A., Shelley, T., López, O. L., & DeKosky, S. T. (2000) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.12.2.233 · Cited by 1,973
Constantino, J. N., Davis, S. A., Todd, R. D., Schindler, M. K., Gross, M. M., Brophy, S. L., Metzger, L. M., Shoushtari, C. S., Splinter, R., & Reich, W. (2003) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1025014929212 · Cited by 1,611
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
(1985) · PubMed · Cited by 1,427
Altered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349
Reliability and validity of a computerized neurocognitive test battery, CNS vital signs
GUALTIERI, C., & JOHNSON, L. (2006) · Archives of Clinical Neuropsychology · doi:10.1016/j.acn.2006.05.007 · Cited by 873 · cited 1×
“CNS VS TheCNSVS is a computerized testing battery focused onworkingmemory; the following four modules were used: Visual Memory Test (VIM), Symbol-Digit Coding (SDC), Perception of Emotions Test (POET), and three-part Continuous Performance Test (CPT) [WorkingMemory Test (WMT)] (31).”
MethodLam, K. S. L., & Aman, M. G. (2007) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0213-z · Cited by 793
Devys, D., Lutz, Y., Rouyer, N., Bellocq, J.-P., & Mandel, J.-L. (1993) · Nature Genetics · doi:10.1038/ng0893-335 · Cited by 780 · cited 1×
“This mutation is associated with complete or partial methylation at the FMR1 promoter, resulting in the loss or significant reduction of expression of the gene product FMRP (fragile X mental retardation protein) (7).”
Background
Research works printed but not linked: 2
- W. Guy in ECDEU Assessment Manual for Psychopharmacology (National Institute of Mental Health Psychopharmacology Research Branch Mental Health Administration Rockville MD 1976) pp. 217–222.
- 10.1176/jnp.12.2.233 · DOI · Paper page
Cited by
Lord, C., Brugha, T. S., Charman, T., Cusack, J., Dumas, G., Frazier, T., Jones, E. J. H., Jones, R. M., Pickles, A., State, M. W., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0138-4 · Cited by 1,859
Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., Tassone, F., Gantois, I., Sonenberg, N., Mandel, J. L., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.65 · Cited by 838
Self-citationDevelopmental timing and critical windows for the treatment of psychiatric disorders
Marín, O. (2016) · Nature Medicine · doi:10.1038/nm.4225 · Cited by 374
Howes, O. D., Rogdaki, M., Findon, J. L., Wichers, R. H., Charman, T., King, B. H., Loth, E., McAlonan, G. M., McCracken, J. T., Parr, J. R., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117741766 · Cited by 342
“Moreover, recent results from two large studies failed to demonstrate any efficacy in the primary endpoint, the ABC-C, (Berry-Kravis et al., 2016) (evidence level Ib) regardless of FMR1 methylation status.”
Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome
Berry-Kravis, E. M., Lindemann, L., Jønch, A. E., Apostol, G., Bear, M. F., Carpenter, R. L., Crawley, J. N., Curie, A., Des Portes, V., Hossain, F., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.221 · Cited by 336
Self-citationLai, M.-C., Anagnostou, E., Wiznitzer, M., Allison, C., & Baron-Cohen, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30034-x · Cited by 250
Metformin ameliorates core deficits in a mouse model of fragile X syndrome
Gantois, I., Khoutorsky, A., Popic, J., Aguilar-Valles, A., Freemantle, E., Cao, R., Sharma, V., Pooters, T., Nagpal, A., Skalecka, A., et al. (2017) · Nature Medicine · doi:10.1038/nm.4335 · Cited by 228
Lemonnier, E., Villeneuve, N., Sonie, S., Serret, S., Rosier, A., Roue, M., Brosset, P., Viellard, M., Bernoux, D., Rondeau, S., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.10 · Cited by 218
The neuropathobiology of multiple sclerosis
Woo, M. S., Engler, J. B., & Friese, M. A. (2024) · Nature Reviews Neuroscience · doi:10.1038/s41583-024-00823-z · Cited by 175
“Treatment of EAE mice with the ubiquitin-specific peptidase 14 (USP14) inhibitor IU1 (which enhances proteasome activity) increased BSN clearance and was neuroprotective 104 , and application of IU1-47, a chemically modified IU1 with higher potency, reduced Box 3”
Arbaclofen in fragile X syndrome: results of phase 3 trials
Berry-Kravis, E., Hagerman, R., Visootsak, J., Budimirovic, D., Kaufmann, W. E., Cherubini, M., Zarevics, P., Walton-Bowen, K., Wang, P., Bear, M. F., et al. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-016-9181-6 · Cited by 183
“It seems clear from the trials reported here and in other trials reported to date [46] that such translation to humans is challenging and that it will be important to learn from these early attempts to improve methodology and the drug development process.”
ResultSelf-citationBorrie, S. C., Brems, H., Legius, E., & Bagni, C. (2017) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091416-035332 · Cited by 165
Updated report on tools to measure outcomes of clinical trials in fragile X syndrome
Budimirovic, D. B., Berry-Kravis, E., Erickson, C. A., Hall, S. S., Hessl, D., Reiss, A. L., King, M. K., Abbeduto, L., & Kaufmann, W. E. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9193-x · Cited by 157
“Considering its initial psychometric evaluation [111], re-assessment [103], and application to FXS trials, in which several subscales have demonstrated sensitivity, the ABC-CFX falls into the moderate-strong category of instruments (two positive randomized placebo-controlled trials: phase 2 mavoglurant [9], phase 3 pe…”
BackgroundMethodInfluentialSelf-citationFragile X targeted pharmacotherapy: lessons learned and future directions
Erickson, C. A., Davenport, M. H., Schaefer, T. L., Wink, L. K., Pedapati, E. V., Sweeney, J. A., Fitzpatrick, S. E., Brown, W. T., Budimirovic, D., Hagerman, R. J., et al. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9186-9 · Cited by 154
“gov Identifiers: NCT01253629, NCT01357239); [76, 79].”
MethodInfluentialSelf-citationSmall Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug–Target Interactions
Lu, S., & Zhang, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01844 · Cited by 158
Ernst, C. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.03.001 · Cited by 145
Opportunities and challenges in modeling human brain disorders in transgenic primates
Jennings, C. G. B., Landman, R., Zhou, Y., Sharma, J., Hyman, J. B., Movshon, J. A., Qiu, Z., Roberts, A., Roe, A. W., Wang, X., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4362 · Cited by 151
Green, J., & Garg, S. (2018) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12892 · Cited by 127
“In FXS, a small open label trial of memantine in six subjects, mean age 18.3 years showed symptom improvement on Clinical Global Impressions (CGI) but no effect on symptom specific rating scales, which included ABC, SRS and ADHD rating scales (Erickson, Mullett, & McDougle, 2009).”
InfluentialFragXis Study Group, Youssef, E. A., Berry-Kravis, E., Czech, C., Hagerman, R. J., Hessl, D., Wong, C. Y., Rabbia, M., Deptula, D., John, A., et al. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.177 · Cited by 133
“…during the study (Rutherford et al, 2011) or a degree of expectation bias, as cited in secretin treatment trials in individuals with autism (Volkmar, 1999) and suggested based upon the substantial improvements during the placebo run-in phase in the mavoglurant trials (Berry-Kravis et al, 2016).”
BackgroundResultInfluentialSelf-citationBerry-Kravis, E. M., Harnett, M. D., Reines, S. A., Reese, M. A., Ethridge, L. E., Outterson, A. H., Michalak, C., Furman, J., & Gurney, M. E. (2021) · Nature Medicine · doi:10.1038/s41591-021-01321-w · Cited by 131
Self-citationA framework for the investigation of rare genetic disorders in neuropsychiatry
Sanders, S. J., Sahin, M., Hostyk, J., Thurm, A., Jacquemont, S., Avillach, P., Douard, E., Martin, C. L., Modi, M. E., Moreno-De-Luca, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0581-5 · Cited by 123
Self-citationBolognani, F., del Valle Rubido, M., Squassante, L., Wandel, C., Derks, M., Murtagh, L., Sevigny, J., Khwaja, O., Umbricht, D., & Fontoura, P. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7838 · Cited by 128
“Similar results were observed in multicenter phase 2 trials of the metabotropic glutamate receptor 5 (mGluR5) antagonists mavoglurant (31) and basimglurant (32) for adolescents and adults with fragile X syndrome and the N-methyl-daspartate receptor antagonist memantine for children with ASD (33).”
ResultHessl, D., Sansone, S. M., Berry-Kravis, E., Riley, K., Widaman, K. F., Abbeduto, L., Schneider, A., Coleman, J., Oaklander, D., Rhodes, K. C., et al. (2016) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-016-9167-4 · Cited by 126
Self-citationLeo Kanner and autism: a 75-year perspective
Harris, J. C. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1455646 · Cited by 186
“For example, in Fragile X syndrome the clinical trial of the mGluR5 antagonist mavoglurant (AFQ056), based on such models, resulted in negative findings in large international clinical trials involving both adult and adolescent subjects (Berry-Kravis et al., 2016).”
BackgroundSidorov, M. S., Deck, G. M., Dolatshahi, M., Thibert, R. L., Bird, L. M., Chu, C. J., & Philpot, B. D. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9195-8 · Cited by 113
“Pharmacological interventions directed towards normalizing protein synthesis were highly successful in correcting Fragile X phenotypes in mice [58 – 60], ultimately leading to multiple phase 2 clinical trials [61, 62].”
Bailey, D. B., Berry-Kravis, E., Wheeler, A., Raspa, M., Merrien, F., Ricart, J., Koumaras, B., Rosenkranz, G., Tomlinson, M., von Raison, F., et al. (2016) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-015-9134-5 · Cited by 101
“Exclusion criteria are presented in detail in the core study paper (Berry-Kravis et al 2015) [27].”
BackgroundSelf-citationFragile X Syndrome: From Molecular Aspect to Clinical Treatment
Protic, D. D., Aishworiya, R., Salcedo‐Arellano, M. J., Tang, S. J., Milisavljevic, J., Mitrovic, F., Hagerman, R. J., & Budimirovic, D. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23041935 · Cited by 120
Self-citationDauvermann, M. R., Lee, G. L., & Dawson, N. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13919 · Cited by 102
“However, research in human subjects has yet to demonstrate an effect of mGlu5-selective drugs on cognition (Berry-Kravis et al., 2016).”
BackgroundDefining Precision Medicine Approaches to Autism Spectrum Disorders: Concepts and Challenges
Loth, E., Murphy, D. G., & Spooren, W. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00188 · Cited by 86
“Also, in some instances, the clinical outcome measure (irritability) did not directly translate to the most consistent behavioral changes identified in the mouse model (learning) (17).”
BackgroundGhatak, S., Talantova, M. V., McKercher, S. R., & Lipton, S. A. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032320-015420 · Cited by 98
Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions
McCracken, J. T., Anagnostou, E. A., Arango, C., Dawson, G., Farchione, T. R., Mantua, V., McPartland, J. C., Murphy, D., Pandina, G., & Veenstra-VanderWeele, J. M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.05.010 · Cited by 98
“2018) and mavoglurant (Berry-Kravis et al., 2016) in FXS were > 50% lower than the samples in positive ASD pivotal trials for risperidone (McCracken et al.”
ResultGenomics in neurodevelopmental disorders: an avenue to personalized medicine
Tărlungeanu, D. C., & Novarino, G. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0129-7 · Cited by 98
Ligsay, A., Van Dijck, A., Nguyen, D. V., Lozano, R., Chen, Y., Bickel, E. S., Hessl, D., Schneider, A., Angkustsiri, K., Tassone, F., et al. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9207-8 · Cited by 80
Self-citationThe origin and natural history of autism spectrum disorders
Harris, J. C. (2016) · Nature Neuroscience · doi:10.1038/nn.4427 · Cited by 95
Molecular Mechanisms of Synaptic Dysregulation in Fragile X Syndrome and Autism Spectrum Disorders
Telias, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00051 · Cited by 83
mGlu5negative allosteric modulators: a patent review (2013 - 2016)
Emmitte, K. A. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1280466 · Cited by 79
Clinical trials in autism spectrum disorder: evidence, challenges and future directions
Anagnostou, E. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000542 · Cited by 72
Protein synthesis levels are increased in a subset of individuals with fragile X syndrome
Jacquemont, S., Pacini, L., Jønch, A. E., Cencelli, G., Rozenberg, I., He, Y., D’Andrea, L., Pedini, G., Eldeeb, M., Willemsen, R., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy099 · Cited by 69
“Drugs targeting group 1 metabotropic glutamate receptors (mGluR1, 5) and GABA receptors have shown very promising results in preclinical studies but a series of large human trials have failed to demonstrate any benefits of these drugs (36).”
BackgroundResultSelf-citationIdentification of FMR1-regulated molecular networks in human neurodevelopment
Li, M., Shin, J., Risgaard, R. D., Parries, M., Wang, J., Chasman, D. A., Liu, S., Roy, S., Bhattacharyya, A., & Zhao, X. (2020) · Genome Research · doi:10.1101/gr.251405.119 · Cited by 83
“from animal models failed to correct disease-related phenotypes in FXS patients (Bailey et al. 2016; Berry-Kravis et al. 2016; Zhao and Bhattacharyya 2018).”
Recent advances in gene therapy for neurodevelopmental disorders with epilepsy
Turner, T. J., Zourray, C., Schorge, S., & Lignani, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15168 · Cited by 71
“…studies on pharmacological inhibition of mGluR5 in FXS mice have had successes (Richter et al. 2015), clinical trials using negative allosteric modulators have failed to date (Berry-Kravis et al. 2016) possibly due to tolerance being developed, which has been observed in mice (Yan et al. 2005).”
BackgroundDisrupted circuits in mouse models of autism spectrum disorder and intellectual disability
Golden, C. E., Buxbaum, J. D., & De Rubeis, S. (2018) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2017.11.006 · Cited by 68
Stoppel, L. J., Auerbach, B. D., Senter, R. K., Preza, A. R., Lefkowitz, R. J., & Bear, M. F. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.075 · Cited by 73
Gregory, K. J., & Goudet, C. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.019133 · Cited by 69
Molecular insights into allosteric modulation of Class C G protein-coupled receptors
Leach, K., & Gregory, K. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.006 · Cited by 67
Wilkerson, J. R., Albanesi, J. P., & Huber, K. M. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.09.035 · Cited by 66
McCamphill, P. K., Stoppel, L. J., Senter, R. K., Lewis, M. C., Heynen, A. J., Stoppel, D. C., Sridhar, V., Collins, K. A., Shi, X., Pan, J. Q., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aam8572 · Cited by 59
“Nevertheless, the outcomes of two clinical studies using 12 weeks of treatment with the mGluR5 NAM mavoglurant (age ranges 12 to 17 and 18 to 45, respectively) were still disappointing (12), leading some to question the applicability of the animal findings to humans (100).”
BackgroundTargeted Reactivation of FMR1 Transcription in Fragile X Syndrome Embryonic Stem Cells
Haenfler, J. M., Skariah, G., Rodriguez, C. M., da Rocha, A. M., Parent, J. M., Smith, G. D., & Todd, P. K. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00282 · Cited by 62
New Targeted Treatments for Fragile X Syndrome
Protic, D. D., Salcedo‐Arellano, M. J., Dy, J. B. S., Potter, L. A., & Hagerman, R. J. (2019) · Current Pediatric Reviews · doi:10.2174/1573396315666190625110748 · Cited by 60
Self-citationAbbeduto, L., Berry‐Kravis, E., Sterling, A. M., Sherman, S. L., Edgin, J. O., McDuffie, A. S., Hoffmann, A., Hamilton, D., Nelson, M. N., Aschkenasy, J. R., et al. (2020) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-020-09313-6 · Cited by 62
Self-citationDíaz-Caneja, C., State, M., Hagerman, R., Jacquemont, S., Marín, O., Bagni, C., Umbricht, D., Simonoff, E., de Andrés-Trelles, F., Kaale, A., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.02.020 · Cited by 55
Self-citationCurrent perspectives in autism spectrum disorder: from genes to therapy
Chahrour, M., O'Roak, B. J., Santini, E., Samaco, R. C., Kleiman, R. J., & Manzini, M. C. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.2335-16.2016 · Cited by 54
“…of what may have been predicted based on observed features in FXS patients (Peier et al., 2000; Spencer et al., 2011), and initial clinical trials targeting mGluR5 signaling in FXS did not result in phenotypic reversal as seen in the mouse model (Dölen et al., 2007; Berry-Kravis et al., 2016).”
BackgroundFragile X syndrome and fragile X-associated disorders
Rajaratnam, A., Shergill, J., Salcedo‐Arellano, M. J., Saldarriaga, W., Duan, X., & Hagerman, R. J. (2017) · F1000Research · doi:10.12688/f1000research.11885.1 · Cited by 61
Self-citationClinical trials for neurodevelopmental disorders: At a therapeutic frontier
Jeste, S. S., & Geschwind, D. H. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9874 · Cited by 51
“(1), negative findings can provide an opportunity opportunity to reflect on clinical trial design and implementation, as well as the underlying mechanistic motivations, and provide lessons for treatment studies of neurodevelopmental disorders in general.”
BackgroundNeurobiologically-based treatments in Rett syndrome: opportunities and challenges
Kaufmann, W. E., Stallworth, J. L., Everman, D. B., & Skinner, S. A. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1229181 · Cited by 50
“No clinical study has replicated the dramatic effects in mouse models [3,4].”
BackgroundReducing histone acetylation rescues cognitive deficits in a mouse model of Fragile X syndrome
Li, Y., Stockton, M. E., Eisinger, B. E., Zhao, L., Miller, J. L., Bhuiyan, I., Gao, Y., Wu, Z., Peng, J., & Zhao, X. (2018) · Nature Communications · doi:10.1038/s41467-018-04869-3 · Cited by 57
Resolving the Synaptic versus Developmental Dichotomy of Autism Risk Genes
Heavner, W. E., & Smith, S. E. P. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.01.009 · Cited by 53
Mingrone, A., Kaffman, A., & Kaffman, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.618593 · Cited by 52
Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors
Stansley, B. J., & Conn, P. J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.02.006 · Cited by 49
“Unfortunately, initial clinical studies have been disappointing and mGlu5 NAMs failed to meet their primary endpoints in reducing symptoms in patients with this syndrome [50].”
BackgroundAchuta, V. S., Grym, H., Putkonen, N., Louhivuori, V., Kärkkäinen, V., Koistinaho, J., Roybon, L., & Castrén, M. L. (2017) · Developmental Neurobiology · doi:10.1002/dneu.22419 · Cited by 44
“…present findings strongly support the potential use of human iPS- derived progenitors for studies elucidating putative species-specific differences of cellular plasticity and differential treatment responses to mGluR5 antagonist in humans with FXS than in Fmr1-KO mice (Berry-Kravis et al., 2016).”
BackgroundResultHagerman, R. J., Jacquemont, S., Berry‐Kravis, E., Portes, V. D., Stanfield, A. C., Koumaras, B., Rosenkranz, G., Murgia, A., Wolf, C., Apostol, G., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-34978-4 · Cited by 49
Self-citationHyperexcitability and impaired intracortical inhibition in patients with fragile-X syndrome
Morin-Parent, F., Champigny, C., Lacroix, A., Corbin, F., & Lepage, J.-F. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0650-z · Cited by 39
Saby, J. N., Peters, S. U., Roberts, T. P. L., Nelson, C. A., & Marsh, E. D. (2020) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2020.00030 · Cited by 47
“The recurrence of failed clinical trials is not unique to Rett syndrome and has also been a point of concern for other neurodevelopmental disorders including Fragile X syndrome (Berry-Kravis et al., 2016; Erickson et al., 2017) and autism spectrum disorder (King et al.”
BackgroundRaspa, M., Bann, C., Gwaltney, A. Y., Benke, T. A., Fu, C., Glaze, D. G., Haas, R., Heydemann, P. T., Jones, M. D., Kaufmann, W. E., et al. (2020) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-125.6.493 · Cited by 45
“In fragile X syndrome, for example, results of a recent clinical trial found that the primary endpoint measure, the Aberrant Behavior Checklist, was not able to detect treatment effects (Berry-Kravis et al., 2016).”
BackgroundLanguage Development in Individuals With Intellectual and Developmental Disabilities
(2016) · International Review of Research in Developmental Disabilities · doi:10.1016/bs.irrdd.2016.05.006 · Cited by 43
Best Practices in Fragile X Syndrome Treatment Development
Erickson, C. A., Kaufmann, W. E., Budimirovic, D. B., Lachiewicz, A. M., Haas‐Givler, B., Miller, R. M., Weber, J. D., Abbeduto, L., Hessl, D. R., Hagerman, R. J., et al. (2018) · Brain Sciences · doi:10.3390/brainsci8120224 · Cited by 45
Self-citationThe Search for an Effective Therapy to Treat Fragile X Syndrome: Dream or Reality?
Castagnola, S., Bardoni, B., & Maurin, T. (2017) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2017.00015 · Cited by 40
“Indeed, the first ever therapeutic strategies to be tested for FXS in clinical trials targeted the glutamatergic system (the excitatory pathway known to be up-regulated in FXS; Bear et al., 2004; Berry-Kravis et al., 2016) and the γ-aminobutyric acid (GABA) system (the inhibitory pathway also dysregulated in the disea…”
BackgroundResultInfluentialChen, Y., Chang, Y., & Huang, Y. (2018) · Developmental Neurobiology · doi:10.1002/dneu.22653 · Cited by 47
Barokova, M. D., Valle, C. L., Hassan, S., Lee, C., Xu, M., McKechnie, R., Johnston, E., Krol, M. A., Leano, J., & Tager-Flusberg, H. B. (2020) · Autism Research · doi:10.1002/aur.2380 · Cited by 45
“Parent report measures are subjective and vulnerable to placebo effects when used in intervention studies [e.g., Berry-Kravis et al., 2016; Guastella et al., 2015; Masi, Lampit, Glozier, Hickie, & Guastella, 2015].”
mGluR5 Negative Modulators for Fragile X: Treatment Resistance and Persistence
Stoppel, D. C., McCamphill, P. K., Senter, R. K., Heynen, A. J., & Bear, M. F. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.718953 · Cited by 40
“However, these studies failed to demonstrate improvements in the primary therapeutic endpoints [26].”
Ray, B., Sokol, D. K., Maloney, B., & Lahiri, D. K. (2016) · Scientific Reports · doi:10.1038/srep26052 · Cited by 44
“However, a larger and better-powered study resulted in no significant differences between mavoglurant and placebo in any group of the study 105 .”
The Fragile X Protein and Genome Function
Dockendorff, T. C., & Labrador, M. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1122-9 · Cited by 41
Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis
Luu, S., Province, H. S., Berry‐Kravis, E., Hagerman, R. J., Hessl, D. R., Vaidya, D. M., Lozano, R., Rosselot, H., Erickson, C. A., Kaufmann, W. E., et al. (2020) · Brain Sciences · doi:10.3390/brainsci10090629 · Cited by 42
“The trials included both total and subscale scores (Irritability (Irr), Social Unresponsiveness/Lethargy/(SU/L), Stereotypy (Stereo), Hyperactivity (Hyper), Inappropriate Speech (Speech) and Social Avoidance (SA) [23,25,26].”
BackgroundSelf-citationChallenges and opportunities for precision medicine in neurodevelopmental disorders
Chen, G. T., & Geschwind, D. H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114564 · Cited by 44
Review of targeted treatments in fragile X syndrome
Ligsay, A., & Hagerman, R. J. (2016) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2016.01045 · Cited by 38
Self-citationGroß, C., Banerjee, A., Tiwari, D., Longo, F., White, A. R., Allen, A. G., Schroeder, L. M., Krzeski, J. C., Elsayed, N. A., Puckett, R. E., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0150-5 · Cited by 40
“So far, clinical trials using mGlu1/5 antagonists have not shown the expected results [10, 11], which has initiated efforts to identify and test other treatment strategies Apart from mGlu1/5, many additional neurotransmitter receptor pathways are affected in FXS, including Gq-coupled, TrkB, or dopamine receptors [3].”
BackgroundSrivastava, S., Jo, B., Zhang, B., Frazier, T. W., Gallagher, A. S., Peck, F. C., Levin, A. R., Mondal, S., Li, Z., Filip‐Dhima, R., et al. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac111 · Cited by 38
“Prior studies in the field have involved shorter study durations [such as 12 weeks for mavoglurant in fragile × syndrome (24)], which may be insufficient for determining treatment response in various cognitive domains.”
BackgroundClinical investigations of compounds targeting metabotropic glutamate receptors
Witkin, J. M., Pandey, K. P., & Smith, J. L. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173446 · Cited by 41
Medical Therapies for Children With Autism Spectrum Disorder—An Update
Edwin Williamson, M. D., Sathe, N. A., & Andrews, J. C. (2017) · doi:10.23970/ahrqepccer189 · Cited by 50
Baker, E. K., Arpone, M., Aliaga, S., Bretherton, L., Kraan, C. M., Bui, M., Slater, H. R., Ling, L., Francis, D. I., Hunter, M. F., et al. (2019) · Molecular Autism · doi:10.1186/s13229-019-0271-7 · Cited by 39
“This may also explain, in part, why preclinical studies in FMR1 knockout (KO) animal models, trialling drugs that correct pathways dysregulated due to complete loss of FMR1, were largely unsuccessful in human trials [43].”
BackgroundResultMolecular Biomarkers in Fragile X Syndrome
Zafarullah, M., & Tassone, F. (2019) · Brain Sciences · doi:10.3390/brainsci9050096 · Cited by 38
“In addition, the reported behavioral effects of stereotypic behavior, hyperactivity, and inappropriate speech were not replicated with FXS male and female adolescents and adults either full or partial FMR1 methylation in subsequent 12-week double-blind mavoglurant studies [75].”
BackgroundEEG as a translational biomarker and outcome measure in fragile X syndrome
Kenny, A., Wright, D., & Stanfield, A. C. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01796-2 · Cited by 38
“Several recent, double-blind, placebocontrolled studies found no benefit of mavoglurant administration on several outcome measures of behavioural characteristics in large FXS cohorts [53, 113, 114].”
BackgroundFelts, A. S., Rodriguez, A. L., Blobaum, A. L., Morrison, R. D., Bates, B. S., Gray, A. T., Rook, J. M., Tantawy, M. N., Byers, F. W., Chang, S., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00410 · Cited by 36
Early Identification of Fragile X Syndrome through Expanded Newborn Screening
Okoniewski, K. C., Wheeler, A., Lee, S., Boyea, B. L., Raspa, M., Taylor, J. L., & Bailey, D. B. (2019) · Brain Sciences · doi:10.3390/brainsci9010004 · Cited by 36
Clinical Development of Targeted Fragile X Syndrome Treatments: An Industry Perspective
Lee, A. W., Ventola, P. E., Budimirovic, D. B., Berry‐Kravis, E., & Visootsak, J. (2018) · Brain Sciences · doi:10.3390/brainsci8120214 · Cited by 39
Self-citationAuditory hypersensitivity and processing deficits in a rat model of fragile X syndrome
Auerbach, B. D., Manohar, S., Radziwon, K. E., & Salvi, R. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105541 · Cited by 36
Carey, C., Singh, N., Dunn, J., Sementa, T., Méndez, M. A., Velthuis, H., Pereira, A. C., Pretzsch, C. M., Horder, J., Hader, S., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02143-1 · Cited by 35
Rare diseases of epigenetic origin: Challenges and opportunities
Fu, M. P., Merrill, S. M., Sharma, M., Gibson, W. T., Turvey, S. E., & Kobor, M. S. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1113086 · Cited by 40
“FMRP has been studied from a variety of perspectives to elucidate the underlying pathophysiology of FXS, and the results have highlighted the challenges in development of therapeutic strategies for RDEOs.”
BackgroundInfluentialSalcedo‐Arellano, M. J., Cabal-Herrera, A. M., Punatar, R., Clark, C. J., Romney, C. A., & Hagerman, R. J. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00968-6 · Cited by 35
Self-citationZhang, D., Qi, Y., Klyubin, I. V., Ondrejčák, T., Sarell, C. J., Cuello, A. C., Collinge, J., & Rowan, M. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.03.036 · Cited by 34
Therapeutic strategies for autism: targeting three levels of the central dogma of molecular biology
Hong, D., & Iakoucheva, L. M. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02356-y · Cited by 36
Bridi, M. S., Schoch, H., Florian, C., Poplawski, S. G., Banerjee, A., Hawk, J. D., Porcari, G. S., Lejards, C., Hahn, C.-G., Giese, K.-P., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.92385 · Cited by 34
Mouse models of fragile X-related disorders
Willemsen, R., & Kooy, R. F. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.049485 · Cited by 31
White matter as a monitoring biomarker for neurodevelopmental disorder intervention studies
Swanson, M. R., & Hazlett, H. C. (2019) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-019-9295-8 · Cited by 31
“While advances in the understanding of FXS pathophysiology led to several candidate drug targets, randomized clinical trials in humans were considered failures [102, 103].”
BackgroundJohnson, J. T., Fila, W. A., & Anumudu, C. K. (2025) · Applied Sciences · doi:10.3390/app151810285 · Cited by 35
“…at rebalancing neuronal excitation-inhibition, such as targeting metabotropic glutamate receptors (mGluRs) or GABAergic receptors, have been in the limelight too, but translation to clinical success has been inconsistent, as evidenced by their limited success in Fragile X syndrome trials [247,248].”
Biased agonism and allosteric modulation of metabotropic glutamate receptor 5
Trinh, P. N. H., May, L. T., Leach, K., & Gregory, K. J. (2018) · Clinical Science · doi:10.1042/cs20180374 · Cited by 29
Enhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development
Kaffman, A., White, J. D., Wei, L., Johnson, F. K., & Krystal, J. H. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9554-7_1 · Cited by 30
Duy, P. Q., & Budimirovic, D. B. (2017) · Translational Neuroscience · doi:10.1515/tnsci-2017-0002 · Cited by 32
Thangarajh, M., Spurney, C. F., Gordish‐Dressman, H., Clemens, P. R., Hoffman, E. P., McDonald, C. M., Henricson, E., & CINRG Investigators (2018) · PLoS Currents · doi:10.1371/currents.md.4cdeb6970e54034db2bc3dfa54b4d987 · Cited by 28
Fragile X syndrome: Are signaling lipids the missing culprits?
Tabet, R., Vitale, N., & Moine, H. (2016) · Biochimie · doi:10.1016/j.biochi.2016.09.002 · Cited by 30
Hessl, D. R., Harvey, D. J., Sansone, S. M., Crestodina, C., Chin, J. A., Joshi, R., Hagerman, R. J., & Berry‐Kravis, E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0209984 · Cited by 26
“Here, we report evidence that mavoglurant (AFQ056, Novartis), an mGluR5 negative allostatic modulator, improves a core phenotypic feature of FXS in the laboratory, despite its failure to show significant behavioral improvement over placebo, in two Phase 2b trials of this compound [2].”
BackgroundResultSelf-citationEmerging pharmacological therapies in fragile X syndrome and autism
Yamasue, H., Aran, A. A., & Berry‐Kravis, E. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000703 · Cited by 28
“Larger placebo-controlled trials of arbaclofen (NCT00788073),AFQ056 (NCT01357239, NCT01253629), and RO4917523 (mGluR5 NAM, NCT01517698), for 3 months in adults and adolescents with FXS have not shown behavioral benefit but have not addressed cognitive or learning outcomes [10,11].”
BackgroundSelf-citation
Metadata
- Authors
- Berry-Kravis, E., Des Portes, V., Hagerman, R., Jacquemont, S., Charles, P., Visootsak, J., Brinkman, M., Rerat, K., Koumaras, B., Zhu, L., Barth, G. M., Jaecklin, T., Apostol, G., & von Raison, F.
- Affiliations
- Departments of Pediatrics, Neurological Sciences, and Biochemistry, Rush University Medical Center, Chicago, IL 60612, USA.
- National Reference Center for Fragile X and Other X-Linked Intellectual Disabilities, CIC 1407 INSERM, Hospices Civils de Lyon, Université de Lyon, 69002 Lyon, France.
- University of California Davis Medical Center (US)
- Centre Hospitalier Universitaire Vaudois (CH)
- Assistance Publique – Hôpitaux de Paris (FR)
- Emory University (US)
- Novartis (Germany) (DE)
- Novartis Pharmaceuticals SAS, 92500 Rueil-Malmaison, France.
- Neurodegeneration Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936–1080, USA.
- Novartis (United States) (US)
- Universitätsklinikum Tübingen (DE)
- Novartis (Switzerland) (CH)
- Neuroscience Development, Novartis Pharma AG, CH-4056 Basel, Switzerland.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-01-13
- Volume
- 8
- Issue
- 321
- Pages
- 321ra5-321ra5
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2237631658
- Cited by
- 270
- References
- 35
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 14 · 2023: 12 · 2022: 23 · 2021: 21 · 2020: 35 · 2019: 29 · 2018: 27 · 2017: 54 · 2016: 22
- FWCI
- 29.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Pharma AG
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Keywords
- fragile X syndrome, metabotropic glutamate receptor 5, mGluR5 antagonist, intellectual disability, autism spectrum disorder, behavioral symptoms, synaptic plasticity, drug safety and efficacy
- MeSH terms
- Adolescent, Adult, Age Factors, Behavior, Cognition, Demography, Double-Blind Method, Female, Fragile X Syndrome, Humans, Indoles, Male, Placebos, Least-Squares Analysis, Treatment Outcome, DNA Methylation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.